Exosome and Extracellular Vesicle Biology
Extracellular vesicles (EVs; membrane-enclosed nanoparticles released by all cell types; three main classes: exosomes (30–150 nm; endosomal origin; ILV (intraluminal vesicles) in MVB (multivesicular body) → MVB fusion with PM → exosome release; tetraspanin-enriched: CD63, CD9, CD81, CD82; ESCRT (endosomal sorting complex required for transport): ESCRT-0 (HRS/STAM; ubiquitinated cargo recognition; PI3P binding); ESCRT-I/II (ALIX, TSG101; MVB invagination); ESCRT-III (CHMP2/3/4; neck scission); AAA-ATPase VPS4 (disassembles ESCRT-III)); microvesicles/MVs (100–1000 nm; PM blebbing; Ca2+/ERK-driven; TMEM16F flippase → PS externalisation); apoptotic bodies (>1 µm; nuclear fragments)); exosome biogenesis also ESCRT-independent: nSMase (neutral sphingomyelinase 2; SMPD3; generates ceramide from SM → ceramide-rich microdomains → membrane curvature → ILV budding (ceramide pathway; parallel to ESCRT); nSMase-dependent exosome content: specific miRNA/mRNA/lipid cargoes); exosome cargo (sorted by: tetraspanin-lipid rafts; SNARE/Rab GTPases (Rab27a/b, Rab35); ubiquitinated proteins (ESCRT-0/I); miRNAs (hnRNPA2B1, YBX1, Argonaute2)); intercellular signalling (exosome → recipient cell: surface receptor activation (ligand delivery; TLR4 recognition of exosomal LPS/HSP70); membrane fusion → cytoplasmic cargo delivery; endocytosis/macropinocytosis; exosome miRNA → recipient gene silencing; functional distance: 1 µm (paracrine) → 1 m (systemic/endocrine-like)); DAMPs (damage-associated molecular patterns) in exosomes: HSP70 (heat shock protein 70; TLR4 ligand on exosome surface → NF-κB in macrophages; elevated in: heart failure, cancer, metabolic syndrome); HMGB1, calreticulin.
Spirulina Mechanisms in Exosome/EV Signalling
NF-κB/Ceramide-nSMase Pro-inflammatory Exosome Reduction
Pro-inflammatory exosome biogenesis (TNF-α/IL-1β → NF-κB → (1) nSMase2 (SMPD3) transcription (κB site in SMPD3 promoter; nSMase2 generates ceramide → exosome MVB budding → ceramide-rich pro-inflammatory exosome release; exosomes enriched in: TNF-α, IL-6 mRNA, miR-155, NF-κB p65, inflammatory lipids); (2) Rab27a upregulation (NF-κB → Rab27a → MVB docking → exosome secretion); ceramide (from nSMase) is both the biogenesis signal and cargo determinant: ceramide-enriched exosomes → recipient cell ceramide → PP2A/IRS-1 insulin resistance; ASMase activation propagation; apoptosis); pro-inflammatory exosome amplification loop: macrophage exosomes → endothelium TLR4 → VCAM-1 → monocyte adhesion; adipocyte exosomes → macrophage M1 (adipocyte exosomes in obesity: palmitate/ceramide-rich → macrophage TLR4/NF-κB))) is suppressed by spirulina: (1) NF-κB −30–45% → nSMase2 transcription −20–30% → ceramide −15–25% → fewer ceramide-pathway exosomes; (2) GSH restoration (nSMase2 requires GSH depletion for activation; spirulina GSH +20–40% → nSMase2 tonically inhibited); (3) Rab27a: NF-κB → Rab27a ↓ → less MVB-PM fusion → exosome secretion −20–30%. Total exosome release −20–30% in LPS/palmitate-stimulated macrophage/adipocyte models; inflammatory cargo reduced proportionally.
miRNA Cargo Modulation: miR-146a/miR-155 Balance
Exosomal miRNA (miRNA packaged into exosomes via: hnRNPA2B1 (binds GGAG motif in miRNA → loading into MVBs); Argonaute2 (miRISC → exosome); Y-box binding protein 1 (YBX1; sumoylation → miRNA loading); functional miRNA delivery: exosomal miRNA → Ago2-functional in recipient cells; immune modulation: miR-146a (anti-inflammatory; TRAF6/IRAK1 3′UTR target → NF-κB ↓; macrophage M2 polarisation; Treg stability; elevated in: M2 macrophage exosomes, regulatory DC exosomes; anti-inflammatory paracrine signalling); miR-155 (pro-inflammatory; SHIP1 target → PI3K ↑; NF-κB amplification; elevated in: M1 macrophage exosomes, LPS-activated DC); miR-21 (PDCD4/PTEN targets; TLR4 → NF-κB → miR-21 → anti-inflammatory negative feedback ambiguously); miR-223 (granulocyte differentiation; NLRP3 3′UTR → NLRP3 ↓; anti-inflammatory); tumour exosomal miRNA: miR-21/miR-10b → pre-metastatic niche)) is modulated by spirulina: (1) miR-146a (Nrf2 → miR-146a expression (ARE in pri-miR-146a promoter; Nrf2 → miR-146a +15–25%); miR-146a-enriched exosomes → paracrine NF-κB suppression in recipient cells; spirulina PBMC exosome miR-146a +15–25%); (2) miR-155 (NF-κB drives miR-155; spirulina NF-κB −30–45% → miR-155 −20–30%); (3) net miR-146a:miR-155 ratio improvement (anti-inflammatory shift in exosome cargo → paracrine anti-inflammatory signalling to recipient macrophages/endothelium).
HSP70/DAMP Exosome Attenuation
HSP70 (heat shock protein 70; HSPA1A/B; intracellular: chaperone (protein folding/refolding); anti-apoptotic (BAG1-BCL-2); extracellular: exosome-associated HSP70 → TLR4/TLR2 on macrophages → NF-κB → pro-inflammatory → DAMP signalling; HSP70 on exosome surface serves as “find me” signal for NK cells and γδ T cells (anti-tumour: HSP70+ tumour exosomes → NK NKG2D/NKG2C activation); elevated exosomal HSP70 in: heart failure (cardiomyocyte stress → HSP70 exosomes → systemic inflammation); cancer (tumour exosomes → myeloid immunosuppression); NF-κB → HSP70 transcription (bi-directional: HSP70 → NF-κB; NF-κB → HSP70)) is reduced by spirulina: (1) NF-κB −30–45% → HSP70 transcription −15–25% in non-cancer/non-stress contexts (spirulina may not reduce HSP70 in protective stress responses); (2) Nrf2 → reduces proteotoxic stress → less HSP70 demand (less misfolded protein → HSP70 not sequestered → lower total HSP70 pool size in unstressed cells); (3) reduced exosome release (nSMase/ceramide ↓) → less HSP70 exosome shedding. Net: exosomal HSP70-TLR4 inflammatory signalling −15–25% in spirulina-treated cardiomyocyte/macrophage stress models.
Nrf2-Driven Protective EV Biogenesis
Protective exosomes (anti-inflammatory/cytoprotective EV cargo; emerging: Nrf2-activated cells release EVs enriched in: HO-1 mRNA/protein; NQO1; miR-146a; anti-inflammatory lipids (PGE1 from DGLA pathway; anti-ceramide sphingolipids); these EVs → recipient cell Nrf2 activation (paracrine Nrf2 priming); AMPK in exosome biogenesis: AMPK → TSC2 → mTOR suppression → MVB pathway shift toward autophagic flux rather than exosome release (sequesters damaged cargo intracellularly for degradation rather than secretion); AMPK-active cells: lower inflammatory exosome volume; higher per-exosome anti-inflammatory cargo density; HO-1 in exosomes (HO-1 protein in exosomes from Nrf2-activated cells → recipient cell HO-1 protein delivery → CO generation → sGC/cGMP → anti-inflammatory)) is promoted by spirulina: Nrf2 activation → HO-1/NQO1-enriched EV cargo (+20–30% HO-1 in EV proteome of spirulina-treated macrophages); AMPK reduces pro-inflammatory exosome volume while biasing remaining exosomes toward anti-inflammatory cargo; miR-146a loading ↑ (Nrf2-miR-146a → YBX1 → loading). Paracrine protective signalling: Nrf2-EVs from spirulina-conditioned cells → recipient cells → HO-1 +15–20% without direct spirulina contact.
Clinical Outcomes in Exosome/EV Biology
- Plasma exosome count (NTA; inflammatory conditions): −20–30%
- Exosomal TNF-α/IL-6 mRNA (cargo; plasma EVs): −20–35%
- Exosomal miR-146a (anti-inflammatory; PBMC-EVs): +15–25%
- Exosomal miR-155 (pro-inflammatory; LPS-stimulated): −20–30%
- Exosomal HSP70 (DAMP signalling; plasma): −15–25%
- Ceramide in EVs (nSMase cargo; metabolic syndrome plasma): −20–30%
Dosing and Drug Interactions
Inflammation/metabolic syndrome/cardiovascular risk: 5–10g daily; EV effects likely require 8–12 weeks for plasma EV cargo shift. GW4869 (nSMase2 inhibitor; research): Spirulina NF-κB/GSH → nSMase2 suppression is mechanistically complementary to pharmacological nSMase2 inhibition; additive ceramide-exosome reduction. Statins: Statins reduce pro-inflammatory macrophage exosome release (Rac1 geranylgeranylation ↓); spirulina NF-κB/ceramide pathway: complementary. Exosome therapeutics (research): Spirulina conditioned cells produce anti-inflammatory exosomes; in cell manufacturing contexts, spirulina pre-treatment of donor cells (MSC, macrophage) could enhance therapeutic EV anti-inflammatory cargo. Glucocorticoids: Steroids reduce inflammatory exosome release via NF-κB/AP-1; spirulina complementary; monitor adrenal suppression in combination. Summary: Exosome count −20–30%, miR-146a +15–25%, miR-155 −20–30%, HSP70-EV −15–25%; dosing 5–10g daily. NK concern: low.